CriticalFirst-generation antihistamine with anxiolytic activity×Synthetic opioid, full mu-receptor agonist
Updated · Methodology
Mechanism
Hydroxyzine is associated with QT prolongation. Post-marketing cases of QT prolongation and torsade de pointes occurred mostly in people with other risk factors, electrolyte disturbances or concomitant medicines (hydroxyzine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). QT prolongation and torsade de pointes have also been reported during methadone treatment, especially at high doses. In laboratory studies, methadone inhibited cardiac potassium channels (methadone SmPC, AEMPS, and label, US Food and Drug Administration, FDA). The Spanish hydroxyzine SmPC names methadone among the drugs that raise the risk of arrhythmia when given with hydroxyzine (AEMPS). The second mechanism is additive central nervous system (CNS) depression. Hydroxyzine potentiates opioids and other CNS depressants, and methadone taken with sedatives or anxiolytics can cause profound sedation, respiratory depression, coma and death (hydroxyzine and methadone SmPCs and labels, AEMPS and FDA). Hydroxyzine inhibits CYP2D6 and at high doses may affect the metabolism of its substrates (AEMPS). CYP2D6 takes part in methadone metabolism, and inhibitors of this enzyme can raise methadone concentrations (methadone label, FDA).
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Torsade de pointes and other ventricular arrhythmias cause palpitations, dizziness and fainting (hydroxyzine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Additive central nervous system depression shows as profound sedation, respiratory depression, low blood pressure and coma, and can be fatal (methadone SmPC, AEMPS, and label, US Food and Drug Administration, FDA). The anticholinergic effect of hydroxyzine together with methadone can cause urinary retention and severe constipation, up to paralytic ileus (hydroxyzine SmPC, AEMPS, and methadone label, FDA).
Management
The combination is contraindicated. The Spanish hydroxyzine summary of product characteristics (SmPC) contraindicates hydroxyzine with drugs that prolong the QT interval and names methadone (hydroxyzine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US hydroxyzine label only advises caution with methadone (hydroxyzine label, US Food and Drug Administration, FDA). Hydroxyzine is also contraindicated in known QT prolongation, cardiovascular disease, low potassium or magnesium, a family history of sudden cardiac death and significant bradycardia (hydroxyzine SmPC, AEMPS). Use methadone with caution in people taking other QT-prolonging drugs. The methadone SmPCs recommend an electrocardiogram (ECG) before treatment, two weeks after the start and before a dose increase (methadone SmPCs, AEMPS). The second risk of the pair is central nervous system (CNS) depression. Hydroxyzine's own SmPC describes it as an anxiolytic with a sedative effect. Combine methadone with sedatives only when no other treatment option is possible, at the lowest effective dose and for the shortest time, and monitor for respiratory depression and sedation (methadone SmPCs, AEMPS). For people on methadone for opioid dependence, the US methadone label prefers stopping the CNS depressant in most cases. It also says not to deny methadone treatment because of the depressant (methadone label, FDA). The US hydroxyzine label says to reduce the dose of CNS depressants, narcotic analgesics included, when they are given with hydroxyzine (hydroxyzine label, FDA). If signs of arrhythmia appear, stop hydroxyzine (hydroxyzine SmPC, AEMPS), and when anticholinergic drugs are added, watch for urinary retention and reduced bowel motility (methadone label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Metadona (nº registro 62423), sección 4.5 (2026)– AEMPS, CIMA, nº registro 62423, sección 4.5
- AEMPS: Ficha técnica: Metadona (Metasedin 40 mg) (nº registro 62423), secciones 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 62423, revisión 05/2026, secciones 4.4 y 4.5
- FDA: Methadone hydrochloride tablets (methadone) prescribing information (2025)– FDA, DailyMed setid 4a44bde6-c348-4316-b0e0-c24b407cb823 (VistaPharm), versión 17, revisión 12/2025, secciones 5.4, 5.9 y 7
- AEMPS: Ficha técnica: Hidroxizina (nº registro 26308), sección 4.5 (2023)– AEMPS, CIMA, nº registro 26308 (Atarax 25 mg comprimidos recubiertos con película, UCB Pharma), revisión 02/2023, secciones 4.3, 4.4, 4.5 y 4.8
- FDA: Hydroxyzine Hydrochloride Tablets, USP (hydroxyzine) prescribing information (2026)– FDA, DailyMed setid 9de2de56-614f-4294-8794-d30758cf5f70 (Aurobindo Pharma), revisión 03/2026 (versión 2), Contraindications, Precautions (QT Prolongation/Torsade de Pointes), Overdosage
- AEMPS: Ficha técnica: Metadona, Eptadone 100 mg solución oral (nº registro 69909), sección 4.4 (2026)– AEMPS, CIMA, nº registro 69909 (Eptadone 100 mg solución oral, L. Molteni & C.), revisión 04/2026, secciones 4.3, 4.4 y 4.5